Cell and Gene Outsourcing

  1. Viral Vector Production: How CDMOs Influence Late-Stage Development Success 10/16/2026

    Late-stage viral vector programs leave almost no margin for error. Regulatory, operational, and market pressures shape the path to commercial launch, and the choice of manufacturing partner carries real weight.

  2. The Early Advantage For IND Success And Beyond 10/16/2026

    Manufacturing decisions made while assembling an IND package shape later cGMP operations and commercial viability. Modality-specific bench-to-IND pathways aim to move programs toward the clinic with fewer downstream surprises.

  3. The Checklist For Evaluating In-Vivo CAR-T Manufacturing Partners 10/16/2026

    Choosing the right in vivo CAR-T manufacturing partner requires looking beyond cost to the capabilities that protect scalability, compliance, safety, and development timelines.

  4. Navigating The Analytical Challenges Of Complex ADCs 10/14/2026

    Antibody drug conjugates are expanding to deliver diverse therapeutic payloads. Advanced analytical strategies are required to characterize these evolving platforms.

  5. Genome Engineering Platforms 10/13/2026

    Leverage the latest genome editing technologies and our exclusive innovations for your mammalian cell line engineering project

     

  6. All You Need To Know About GMP Manufacturing Of mRNA-LNP Drug Products 10/13/2026

    Moving mRNA-LNP production from lab to GMP scale exposes tensions among formulation consistency, regulatory expectations, and facility safety, while automation offers ways to resolve them.

  7. Top 5 Things To Know About The Lipid Nanoparticle Portfolio 10/13/2026

    Lipids that shift charge with pH can be chosen to fit the application and delivery route. Varied pKa and biodegradability give developers room to match each therapeutic target.

  8. Expand mRNA-LNP Nanomedicine Potential By Optimizing Lipids 10/13/2026

    Ionizable lipid selection ratios shape how well lipid nanoparticles deliver nucleic acids, and empirical testing shows that similar physical properties can still produce very different performance.

  9. Avoiding The Pitfalls: 5 Lessons For Cell Therapy Manufacturing Success 10/13/2026

    Cell therapy programs often stall between clinical and commercial supply because of manufacturing readiness, not clinical performance. Five recurring pitfalls, from partner choice to automation, show where early planning matters.

  10. Overcoming Lentiviral Vector Challenges Through Strategic CDMO Partnerships 10/9/2026

    Lentiviral vector fragility, impurity overlap, and the lack of tools to separate full from empty particles complicate downstream processing, while emerging analytics and outsourced manufacturing expertise change how early developers respond.